Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL positive |
| Therapy | Bemcentinib + Cetuximab |
| Indication/Tumor Type | head and neck squamous cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | head and neck squamous cell carcinoma | sensitive | Bemcentinib + Cetuximab | Preclinical | Actionable | In a preclinical study, BGB-324 and Erbitux (cetuximab) worked synergistically to inhibit proliferation of Axl-positive head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293). | 25767293 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25767293) | AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. | Full reference... |